Mkts

Kymera Therapeutics, Inc.

NASDAQ: KYMR
$121.13-0.39 (-0.32%)
As of Nov 18, 9:30 AM ET

Key statistics

Day range
119.83127.45
52-week range
62.91142.92
Today
Open120.38
Previous close121.13
Volume677.5K
Valuation
Market cap9.03B
P/E ratio—
EPS (TTM)-3.24
Income & risk
Dividend / yield—
Beta2.05
Avg volume926.9K
Discussion

KYMR News

Stories mentioning KYMR from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue34,3652,8712,76411,47622,1007,3943,74125,650
Cost of Goods Sold34,3652,8712,76411,47622,1007,3943,74125,650
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development98,16283,83174,09478,38880,25571,81760,41059,202
Sales General & Admin
Total Operating Expenses118,519100,76695,28596,03396,52688,14975,86576,575
Operating Income (Loss)(84,154)(97,895)(92,521)(84,557)(74,426)(80,755)(72,124)(50,925)
Interest Income
Interest Expense
Other Expense14,92010,91410,3467,9438,84510,0039,6378,863
Pretax Income
Tax Provision
Net Income (Loss)(69,234)(86,981)(82,175)(76,614)(65,581)(70,752)(62,487)(42,062)
Earnings Per Share (Basic)(0.71)(1.03)(0.94)(0.95)(0.82)(0.94)(0.82)(0.58)
Earnings Per Share (Diluted)(0.71)(1.03)(0.94)(0.95)(0.82)(0.94)(0.82)(0.58)
Weighted Average Shares Outstanding (Basic)97,53484,49187,30080,44980,14775,04476,12673,059
Weighted Average Shares Outstanding (Diluted)97,53484,49187,30080,44980,14775,04476,12673,059

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About KYMR

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a stock listed on the Nasdaq Stock Market under the ticker symbol KYMR. It last traded at $121.13 (Nov 18, 2026, 9:30 AM ET), down 0.3% on the day. That gives Kymera Therapeutics a market capitalisation of $9.0B.

Over the past 52 weeks KYMR has traded between $62.91 and $142.92.

Revenue for the quarter ended Mar 31, 2026 was $34.4M; a net loss of $69.2M. Revenue was up 55.5% from $22.1M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$34.4M-$69.2M-201.5%
Dec 31, 2025$2.9M-$87.0M-3029.6%
Sep 30, 2025$2.8M-$82.2M-2973.0%
Jun 30, 2025$11.5M-$76.6M-667.6%

From Kymera Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…